2024
Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials
Pulaski H, Mehta S, Manigat L, Kaufman S, Hou H, Nalbantoglu I, Zhang X, Curl E, Taliano R, Kim T, Torbenson M, Glickman J, Resnick M, Patel N, Taylor C, Bedossa P, Montalto M, Beck A, Wack K. Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials. The Journal Of Pathology Clinical Research 2024, 10: e12395. PMID: 39294925, PMCID: PMC11410674, DOI: 10.1002/2056-4538.12395.Peer-Reviewed Original ResearchConceptsClinical trialsAssessment of disease activityOverall percent agreementLiver biopsyDisease activityPathological assessmentWashout periodHistological assessmentEndpoint assessmentGold standardPercent agreementScoring systemExpert pathologistsSteatohepatitisAverage agreementDigital scoresPathologistsTrials
2018
The impact of diet‐induced hepatic steatosis in a murine model of hepatic ischemia/reperfusion injury
Liss KHH, McCommis KS, Chambers KT, Pietka TA, Schweitzer GG, Park SL, Nalbantoglu I, Weinheimer CJ, Hall AM, Finck BN. The impact of diet‐induced hepatic steatosis in a murine model of hepatic ischemia/reperfusion injury. Liver Transplantation 2018, 24: 908-921. PMID: 29729104, PMCID: PMC6097916, DOI: 10.1002/lt.25189.Peer-Reviewed Original ResearchConceptsDiet-induced hepatic steatosisSteatotic liversHepatic steatosisReperfusion injuryLiver diseaseMicrovesicular steatosisMurine modelObesity-associated nonalcoholic fatty liver diseaseHepatic ischemia/reperfusion injuryEnd-stage liver diseaseIschemia/reperfusion injuryNonalcoholic fatty liver diseasePlasma alanine aminotransferase levelsAlanine aminotransferase levelsFatty liver diseaseCriteria donor organsInflammatory cytokine concentrationsPotential therapeutic approachHepatic IRISteatotic graftsLiver transplantationAminotransferase levelsCommon indicationNonalcoholic steatohepatitisOrgan failure
2014
Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu I, Brunt E. Role of liver biopsy in nonalcoholic fatty liver disease. World Journal Of Gastroenterology 2014, 20: 9026-37. PMID: 25083076, PMCID: PMC4112884, DOI: 10.3748/wjg.v20.i27.9026.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseFatty liver diseaseLiver diseaseLiver biopsyPediatric nonalcoholic fatty liver diseaseNASH Clinical Research NetworkLocation of fibrosisSpecific histologic lesionsCardiovascular risk factorsExcess alcohol intakeChronic liver diseaseClinical Research NetworkClinical research trialsLiver biopsy evaluationLimitations of biopsyNon-invasive testingImportant liver diseaseHepatic manifestationNecroinflammatory activityMetabolic syndromeAlcohol intakeHistologic findingsHepatic triglyceridesRisk factorsBiopsy evaluation
2007
Ischemic Preconditioning and Intermittent Clamping Increase the Tolerance of Fatty Liver to Hepatic Ischemia-Reperfusion Injury in the Rat
Saidi R, Chang J, Brooks S, Nalbantoglu I, Adsay V, Jacobs M. Ischemic Preconditioning and Intermittent Clamping Increase the Tolerance of Fatty Liver to Hepatic Ischemia-Reperfusion Injury in the Rat. Transplantation Proceedings 2007, 39: 3010-3014. PMID: 18089311, DOI: 10.1016/j.transproceed.2007.09.044.Peer-Reviewed Original ResearchConceptsContinuous clampingIntermittent clampingIschemic preconditioningR injuryLiver I/R injuryAspartate aminotransferaseLiver ischemia-reperfusion injurySerum IL-6 levelsHours of reperfusionIL-6 levelsIschemia-reperfusion injuryCause of morbidityMale Zucker ratsHepatic ischemiaSerum interleukinHepatocellular injurySerum levelsIschemic periodUntoward sequelaeHepatic steatosisLiver surgeryZucker ratsCellular injuryInjuryMinutes